Entity Detail — Knowledge Graph Node
This page aggregates everything SciDEX knows about NAD: its mechanistic relationships (Knowledge Graph edges), hypotheses targeting it, analyses mentioning it, and supporting scientific papers. The interactive graph below shows its immediate neighbors. All content is AI-synthesized from peer-reviewed literature.
NAD is a concept in neurodegeneration research. Key relationships include: activates, regulates, associated with. Associated with AD, ADH, ALI. Connected to 546 entities in the SciDEX knowledge graph.
| Name | NAD |
| Summary | Biotechnology company specializing in NAD+ precursors and anti-aging research, developing nicotinamide riboside (NR) for neurodegenerative diseases |
| Key Genes/Proteins | AGING, SIRT1, MITOCHONDRIA |
| Related Diseases | Aging, Inflammation, Als, Cancer, Obesity |
| Linked Hypotheses | 6 hypotheses |
Knowledge base pages for this entity
graph TD
NAD["NAD"]
NAD -->|"regulates"| neuronal_bioenergetics["neuronal bioenergetics"]
NAD -->|"regulates"| oxidative_stress["oxidative stress"]
NAD -->|"regulates"| epigenetic_changes["epigenetic changes"]
NAD -->|"regulates"| Tumor["Tumor"]
NAD -->|"regulates"| Neurodegeneration["Neurodegeneration"]
NAD -->|"regulates"| Cancer["Cancer"]
NAD -->|"regulates"| Autoimmune["Autoimmune"]
NAD -->|"activates"| Aging["Aging"]
NAD -->|"regulates"| Cardiovascular["Cardiovascular"]
NAD -->|"causes"| Inflammation["Inflammation"]
cd38["cd38"] -->|"regulates"| NAD
P7C3_A20["P7C3-A20"] -->|"activates"| NAD
ATP["ATP"] -->|"causes"| NAD
CD38["CD38"] -->|"regulates"| NAD
CIRCADIAN_RHYTHM["CIRCADIAN RHYTHM"] -->|"regulates"| NAD
DNA["DNA"] -->|"contributes to"| NAD
SIRT6["SIRT6"] -->|"inhibits"| NAD
EGR2["EGR2"] -->|"inhibits"| NAD
PARP1["PARP1"] -->|"inhibits"| NAD| Target | Relation | Type | Str |
|---|---|---|---|
| AGING | activates | gene | 1.00 |
| Aging | activates | disease | 1.00 |
| SIRT1 | regulates | gene | 1.00 |
| Inflammation | activates | disease | 1.00 |
| SIRT1 | associated_with | gene | 1.00 |
| MITOCHONDRIA | activates | gene | 1.00 |
| Aging | regulates | disease | 1.00 |
| Als | activates | disease | 1.00 |
| Als | regulates | disease | 1.00 |
| AGING | regulates | gene | 1.00 |
| SIRT1 | activates | gene | 1.00 |
| Cancer | regulates | disease | 0.95 |
| Obesity | activates | disease | 0.95 |
| Neurodegeneration | activates | disease | 0.95 |
| Cancer | activates | disease | 0.95 |
| Inflammation | regulates | disease | 0.95 |
| aging | activates | disease | 0.90 |
| aging | implicated_in | disease | 0.90 |
| NAMPT | metabolizes | gene | 0.90 |
| CANCER | regulates | gene | 0.90 |
| INFLAMMATION | activates | gene | 0.90 |
| Mtor | activates | pathway | 0.90 |
| NEURODEGENERATIVE DISEASES | activates | gene | 0.90 |
| MITOCHONDRIAL DYSFUNCTION | activates | gene | 0.90 |
| Oxidative Phosphorylation | activates | pathway | 0.90 |
| NEURODEGENERATION | activates | gene | 0.90 |
| Glycolysis | activates | pathway | 0.90 |
| OXIDATIVE STRESS | activates | gene | 0.90 |
| Oxidative Stress | activates | pathway | 0.90 |
| AMPK | activates | gene | 0.90 |
| CANCER | activates | gene | 0.90 |
| APOPTOSIS | therapeutic_target | gene | 0.90 |
| Apoptosis | therapeutic_target | pathway | 0.90 |
| Tumor | regulates | disease | 0.85 |
| Aging | associated_with | disease | 0.85 |
| Diabetes | activates | disease | 0.85 |
| Parkinson | activates | disease | 0.85 |
| Alzheimer | activates | disease | 0.85 |
| Senescence | therapeutic_target | disease | 0.85 |
| Inflammation | therapeutic_target | disease | 0.85 |
| NAD+ metabolism | participates_in | pathway | 0.85 |
| DAM microglia | expressed_in | cell_type | 0.85 |
| aging | associated_with | disease | 0.80 |
| NAMPT | implicated_in | gene | 0.80 |
| T cells | expressed_in | cell_type | 0.80 |
| senescence | participates_in | pathway | 0.80 |
| ALZHEIMER | activates | gene | 0.80 |
| PARKINSON | activates | gene | 0.80 |
| Mitophagy | activates | pathway | 0.80 |
| MTOR | activates | gene | 0.80 |
| Source | Relation | Type | Str |
|---|---|---|---|
| nicotinamide | targets | drug | 0.85 |
| P7C3-A20 | activates | drug | 0.70 |
| AGING | associated_with | gene | 0.70 |
| CD38 | implicated_in | gene | 0.70 |
| ATP | releases | gene | 0.70 |
| DNA | disrupts | gene | 0.70 |
| CANCER | interacts_with | disease | 0.65 |
| MACROPHAGE | activates | cell_type | 0.65 |
| MONOCYTE | activates | cell_type | 0.65 |
| AMPK | activates | gene | 0.65 |
| MTOR | regulates | gene | 0.65 |
| ENDOTHELIAL | regulates | cell_type | 0.65 |
| APP | inhibits | gene | 0.65 |
| ALZHEIMER'S DISEASE | associated_with | disease | 0.65 |
| ATP | regulates | gene | 0.65 |
| BMAL1 | activates | gene | 0.65 |
| CLOCK | activates | gene | 0.65 |
| ATP | causes | gene | 0.60 |
| CD38 | associated_with | gene | 0.60 |
| P2RY1 | associated_with | gene | 0.60 |
| ADORA2B | associated_with | gene | 0.60 |
| P2RX1 | associated_with | gene | 0.60 |
| P2RY12 | associated_with | gene | 0.60 |
| CD38 | regulates | gene | 0.60 |
| CIRCADIAN RHYTHM | regulates | gene | 0.60 |
| DNA | contributes_to | gene | 0.60 |
| CD38 | inhibits | gene | 0.60 |
| SIRT6 | inhibits | gene | 0.60 |
| EGR2 | inhibits | gene | 0.60 |
| PARP1 | inhibits | gene | 0.60 |
| MITOCHONDRIAL DYSFUNCTION | associated_with | gene | 0.60 |
| MTDNA | activates | gene | 0.60 |
| MTOR | activates | gene | 0.60 |
| AKT | activates | gene | 0.60 |
| JUN | activates | gene | 0.60 |
| ATP | activates | gene | 0.60 |
| MITOCHONDRIAL DYSFUNCTION | activates | gene | 0.60 |
| MITOPHAGY | activates | gene | 0.60 |
| IDO1 | associated_with | gene | 0.60 |
| ASTROCYTES | expressed_in | gene | 0.60 |
| ALZHEIMER'S DISEASE | activates | gene | 0.60 |
| IDH2 | regulates | gene | 0.60 |
| NADH | regulates | gene | 0.60 |
| IDH1 | regulates | gene | 0.60 |
| CANCER | regulates | gene | 0.60 |
| NEURODEGENERATION | regulates | gene | 0.60 |
| NEURON | regulates | gene | 0.60 |
| PARP1 | activates | gene | 0.60 |
| AGING | activates | gene | 0.60 |
| P2RX5 | associated_with | gene | 0.60 |
Hypotheses where this entity is a therapeutic target
| Hypothesis | Score | Disease | Analysis |
|---|---|---|---|
| SARM1-Mediated NAD+ Depletion as Terminal Executor of MCT1-D | 0.614 | neurodegeneration | What is the molecular mechanism by which |
| Senescence-Activated NAD+ Depletion Rescue | 0.604 | neurodegeneration | Senolytic therapy for age-related neurod |
| Metabolic NAD+ Salvage Pathway Enhancement Through NAMPT Ove | 0.592 | neurodegeneration | Epigenetic reprogramming in aging neuron |
| Mitochondrial NAD+ Salvage Enhancement | 0.426 | neurodegeneration | Gene expression changes in aging mouse b |
| SIRT6-NAD+ Axis Enhancement Therapy | 0.395 | neurodegeneration | Epigenetic clocks and biological aging i |
Scientific analyses that reference this entity
neurodegeneration | 2026-04-04 | 0 hypotheses
Scientific publications cited in analyses involving this entity
| Title & PMID | Authors | Journal | Year | Citations |
|---|---|---|---|---|
| Channeling Nicotinamide Phosphoribosyltransferase (NAMPT) to Address Life and De [PMID:38580317] | Velma GR, Krider IS, Alves ETM, Courey J | J Med Chem | 2024 | 1 |
| SIRT6-regulated macrophage efferocytosis epigenetically controls inflammation re [PMID:36593966] | Li B, Xin Z, Gao S, Li Y, Guo S, Fu Y, X | Theranostics | 2023 | 1 |
| Assessing the Status of Mandatory Tuberculosis Case Notification among Private P [PMID:35068738] | Duggal K, Elsy M, Majella MG, Akkilagunt | Indian J Community Med | 2021 | 1 |
| Nicotinamide mononucleotide increases muscle insulin sensitivity in prediabetic [PMID:33888596] | Yoshino M, Yoshino J, Kayser BD, Patti G | Science | 2021 | 1 |
| NAD(+) metabolism, stemness, the immune response, and cancer. [PMID:33384409] | Navas LE, Carnero A | Signal Transduct Target Ther | 2021 | 1 |
| Protocol for the Bottom-Up Proteomic Analysis of Mouse Spleen. [PMID:33377090] | Dowling P, Gargan S, Zweyer M, Henry M, | STAR Protoc | 2020 | 1 |
| Dynamic Acetylation of Phosphoenolpyruvate Carboxykinase Toggles Enzyme Activity [PMID:30193097] | Latorre-Muro P, Baeza J, Armstrong EA, H | Mol Cell | 2018 | 1 |
| NAD metabolism fuels human and mouse intestinal inflammation. [PMID:28877980] | Gerner RR, Klepsch V, Macheiner S, Arnha | Gut | 2018 | 1 |
| The SWI/SNF Protein PBRM1 Restrains VHL-Loss-Driven Clear Cell Renal Cell Carcin [PMID:28329682] | Nargund AM, Pham CG, Dong Y, Wang PI, Os | Cell Rep | 2017 | 1 |
| Mitochondrial Dysfunction Induces Senescence with a Distinct Secretory Phenotype [PMID:26686024] | Wiley CD, Velarde MC, Lecot P, Liu S, Sa | Cell Metab | 2016 | 1 |
| NAD+ and sirtuins in aging and disease. [PMID:24786309] | Imai S, Guarente L | Trends Cell Biol | 2014 | 1 |
| Mitochondrial NAD(+)-mediated mitophagy alleviates type I interferon response to [PMID:41231107] | Lan T, Shang D, Lin L, Wang H, Zou J et | Autophagy | 2026 | 0 |
| cGAS-STING signaling in Alzheimer's disease: Microglial mechanisms and therapeut [PMID:41481960] | Fazal F, Dar NJ, Ahamad S, Khan S, Bano | Mol Aspects Med | 2026 | 0 |
| Opportunities and challenges of targeting cGAS-STING in cancer. [PMID:41486397] | Lu C, Wang W, Fu YX | Nat Rev Cancer | 2026 | 0 |
| CircZBTB44-Encoded Peptide ZBTB44-342aa Alleviates Aortic Valve Calcification Vi [PMID:41487094] | Hu D, Lin Y, Huang H, Xian G, Chen Y et | Circ Res | 2026 | 0 |
| Inhibiting macrophage-derived lactate transport restores cGAS-STING signalling a [PMID:41495200] | Li D, Cui G, Yang K, Lu C, Jiang Y et al | Nat Cell Biol | 2026 | 0 |
| cGAS-STING activation in Parkinson's Disease: From mechanisms to Disease-Modifyi [PMID:41500413] | Solomon J, Mandal S, Aran KR | Gene | 2026 | 0 |
| Ubiquitination-directed cytosolic DNA degradation governs cGAS-STING-mediated im [PMID:41512867] | Li L, Ye Q, Ma J, Wang Z, Liu T et al. | Cancer Cell | 2026 | 0 |
| Neuronal TLR4 upregulation activates the cGAS-STING pathway to induce ferroptosi [PMID:41702081] | Qin H, Yang L, Du J, Xu X, Chen Z et al. | Int Immunopharmacol | 2026 | 0 |
| EsxN drives ISG15-mediated dsDNA release to activate cGAS-STING signaling and pr [PMID:41738749] | Zhang Q, Abudukadier A, Chen H, Xiong L, | Microbiol Spectr | 2026 | 0 |